Macrogenenics sold-off 75% from a moderately bad earnings miss 2 weeks ago. It will be a slow and gradual recovery in the 10 -12 weeks until the next earnings unless a favorable catalyst appears. 5 patients died in a clinical study about the same time as earnings were due. This was a news catalyst amplifying the earnings miss. What is unclear is the total...
FSMA Rule 204 is coming into effect after the State of California won a lawsuit against the US Federal Government to enforce the law that was passed but sitting idle since the Obama Admin. Park City Group, Inc. owns the software Repositrak that has the most accreditation from the food safety industry. CEO has the pep in his step as the demand for food traceability...
RZLT is a biotechnology company which has products in clinical development. Many are aware that means rigorous clinical trials before an FDA approval and a product line that generates earnings. Stock price is more about growth and potential more than anything else. That said the chart looks good and I sense there is momentum heading into earnings in the next...
937K shares, 2.2M marketcap micro float. ADHD 1 dose medicine advancing through trials with FDA guidance. I wouldn't be surprised to see NASDAQ:ARCT , NASDAQ:DRRX , or NASDAQ:NLSP buy them up! Do your own due diligence. Do not take this as financial advice. I own shares in this company.
EBS is a small biotechnology company whose forte is the clean processing and manufacturing facility that the FDA requires for certain bioprocessing to be certified for delivery of products to end-user patients. It is not a research facility like the one in China that accidentally released COVID and the global impact will be likely felt for another decade. ...
EVFM Evofem Biosciences has a big upcoming catalyst: Its Phase 3 clinical trial evaluating Phexxi for the prevention of chlamydia and gonorrhea in women is on track to report top-line data from this landmark trial in mid-October, so we are one week away from results! Positive study outcomes would enable potential U.S. approval for prevention of these sexually...
$EVFM produces the only FDA approved hormone-free contraceptive & developing products preventing STIs & HIV. Phase 3 trial results coming later this year. High demand for contraceptives after Roe v. Wade was overturned. www.cnn.com
Clarus Therapeutics Holdings, Inc. (CRXT) Announced Initiation of Phase 4 Clinical Trial of JATENZO, the first and only FDA-approved oral softgel for testosterone replacement therapy in adult male. On 3/31/2022 Serge Belanger from Needham & Company LLC brokerage set a Buy Rating for CRXT and a Price Target of $8.00, which is 9 times higher than the current...
AYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome. After the bullish news, AYTU stock hit the all time low level. 52 Week Range 0.76 - 7.20 LADENBURG THALM has a price target of $14.50 for the stock. I think a reversal is...
Aridis Pharmaceuticals announced first Investor call of 2022 for today, after the closing bell. Exiting pipeline with 2 phase 3 drugs and their monoclonal antibody cocktail. AstraZeneca PLC (AZN) has a stake in this company. CEO has co-developed several drug which have been sold to Astra Zeneca, Megabits and MedImmune. Aridis Pharmaceuticals can be a potential...
Moleculin Biotech`s Annamycin has Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases. the FDA agreed with Moleculin Biotech`s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward. This should be an interesting year for MBRX, which...
AEterna has a variety of new products in its pipeline. Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency. AEterna received European approval to market Macrillen. Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the...
A multi-year trend analysis to see if upcoming catalyst will push upward momentum past current resistance highs.
Quoin Pharmaceuticals (NASDAQ: QNRX ) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed Multiple Exclusive Distribution Agreements for in various regions of the globe for its Lead Asset, QRX003, for Netherton Syndrome. JMP Securities...
On 8/17/2021 Canaccord Genuity brokerage Lower Price Target for SESN giving a Buy rating from $7.00 to $3.00. Sesen Bio (SESN) flagship drug candidate Vicineum, failed to obtain FDA approval, but they will try a second time to get the regulatory go-ahead for the bladder cancer treatment. buying long term calls could be a strategy for this one. volatility is...
Headline Potential Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug: Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant Vaxneuvance, a pneumococcal vaccine Lynparza, a breast cancer drug Merck also...
Yesterday, JMP Securities Initiated Coverage on Quoin Pharmaceuticals, Ltd. (QNRX) with a Market Outperform rating and a price target of 8usd. Quoin Pharmaceuticals (NASDAQ: QNRX) is positioned to deliver the first FDA-approved treatment for Netherton Syndrome, a devastating disorder which affects 1 in every 200,000 people worldwide. This month, QNRX Signed...
Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is...